Total Payments
$2,855
2024 Payments
$1,016
Companies
13
Transactions
147
Medicare Patients
6,959
Medicare Billing
$714,169
Payment Breakdown by Category
Food & Beverage$2,765 (96.8%)
Education$90.60 (3.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,765 | 141 | 96.8% |
| Education | $90.60 | 6 | 3.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $1,515 | 79 | $0 (2024) |
| GlaxoSmithKline, LLC. | $453.68 | 33 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $403.43 | 20 | $0 (2024) |
| Allergan Inc. | $128.16 | 2 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $108.98 | 1 | $0 (2018) |
| Teva Pharmaceuticals USA, Inc. | $57.01 | 3 | $0 (2022) |
| Merck Sharp & Dohme LLC | $52.27 | 3 | $0 (2024) |
| Genentech USA, Inc. | $38.00 | 1 | $0 (2018) |
| United Therapeutics Corporation | $25.41 | 1 | $0 (2024) |
| Baxter Healthcare | $21.88 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,016 | 39 | AstraZeneca Pharmaceuticals LP ($535.86) |
| 2023 | $359.76 | 19 | AstraZeneca Pharmaceuticals LP ($270.07) |
| 2022 | $274.02 | 15 | AstraZeneca Pharmaceuticals LP ($176.79) |
| 2021 | $184.23 | 13 | AstraZeneca Pharmaceuticals LP ($145.84) |
| 2020 | $218.11 | 16 | AstraZeneca Pharmaceuticals LP ($134.01) |
| 2019 | $109.24 | 8 | AstraZeneca Pharmaceuticals LP ($42.65) |
| 2018 | $531.72 | 26 | Allergan Inc. ($128.16) |
| 2017 | $162.07 | 11 | AstraZeneca Pharmaceuticals LP ($88.88) |
All Payment Transactions
147 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | United Therapeutics Corporation | — | Food and Beverage | In-kind items and services | $25.41 | General |
| 11/15/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $29.99 | General |
| Category: Respiratory | ||||||
| 10/29/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $22.54 | General |
| Category: Respiratory | ||||||
| 10/10/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $12.44 | General |
| Category: RESPIRATORY | ||||||
| 10/09/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $18.00 | General |
| Category: Respiratory | ||||||
| 10/03/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $69.58 | General |
| Category: IMMUNOLOGY | ||||||
| 10/03/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $30.08 | General |
| Category: RESPIRATORY | ||||||
| 09/25/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $112.64 | General |
| Category: Respiratory | ||||||
| 09/17/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $25.85 | General |
| Category: Respiratory | ||||||
| 09/13/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $24.80 | General |
| Category: Respiratory | ||||||
| 08/29/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $24.38 | General |
| Category: IMMUNOLOGY | ||||||
| 08/27/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $29.00 | General |
| Category: Respiratory | ||||||
| 07/18/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $27.23 | General |
| Category: Respiratory | ||||||
| 07/11/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $16.41 | General |
| Category: RESPIRATORY | ||||||
| 07/08/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $16.64 | General |
| Category: RESPIRATORY | ||||||
| 07/03/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $13.18 | General |
| Category: Respiratory | ||||||
| 06/10/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | STIOLTO RESPIMAT (Drug) | Food and Beverage | In-kind items and services | $28.57 | General |
| Category: RESPIRATORY | ||||||
| 06/06/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $19.89 | General |
| 06/06/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $7.97 | General |
| Category: RESPIRATORY | ||||||
| 06/04/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $30.80 | General |
| Category: IMMUNOLOGY | ||||||
| 05/31/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $27.38 | General |
| Category: RESPIRATORY | ||||||
| 05/28/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $24.80 | General |
| Category: Respiratory | ||||||
| 04/26/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $20.13 | General |
| Category: Respiratory | ||||||
| 04/18/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $13.39 | General |
| Category: Respiratory | ||||||
| 04/08/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Food and Beverage | In-kind items and services | $20.80 | General |
| Category: CARDIOVASCULAR | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 1,097 | 1,399 | $420,376 | $69,007 |
| 2022 | 10 | 1,420 | 1,616 | $354,439 | $79,584 |
| 2021 | 12 | 2,057 | 3,476 | $719,280 | $205,491 |
| 2020 | 14 | 2,385 | 5,401 | $1.0M | $360,087 |
Total Patients
6,959
Total Services
11,892
Medicare Billing
$714,169
Procedure Codes
49
All Medicare Procedures & Services
49 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 198 | 345 | $106,176 | $29,438 | 27.7% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 259 | 384 | $205,401 | $9,648 | 4.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 76 | 76 | $30,715 | $8,615 | 28.0% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 199 | 208 | $23,020 | $6,992 | 30.4% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 164 | 172 | $20,243 | $5,906 | 29.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 49 | 55 | $11,942 | $3,173 | 26.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 12 | 12 | $5,796 | $1,535 | 26.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 14 | 15 | $4,949 | $1,500 | 30.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 13 | 19 | $3,297 | $1,153 | 35.0% |
| 94618 | Test for exercise-induced lung stress | Facility | 2023 | 21 | 21 | $522.69 | $354.06 | 67.7% |
| 94726 | Test to determine lung volumes using sensors | Facility | 2023 | 29 | 29 | $2,739 | $253.96 | 9.3% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2023 | 34 | 34 | $2,163 | $248.96 | 11.5% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2023 | 29 | 29 | $3,413 | $189.28 | 5.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 309 | 383 | $59,380 | $22,127 | 37.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 152 | 152 | $53,536 | $17,519 | 32.7% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2022 | 381 | 470 | $136,647 | $12,039 | 8.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 97 | 107 | $29,188 | $10,156 | 34.8% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2022 | 192 | 205 | $39,233 | $8,412 | 21.4% |
| 94727 | Test to determine lung volumes using gas dilution or washout | Office | 2022 | 148 | 148 | $25,900 | $4,478 | 17.3% |
| 94726 | Test to determine lung volumes using sensors | Office | 2022 | 63 | 63 | $4,715 | $2,403 | 51.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 52 | 61 | $4,960 | $2,062 | 41.6% |
| 94016 | Test to measure expiratory airflow and volume initiated by patient and evaluated by provider | Office | 2022 | 11 | 11 | $385.00 | $211.01 | 54.8% |
| 94664 | Evaluation of use of breathing device | Office | 2022 | 15 | 16 | $494.04 | $177.51 | 35.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 207 | 1,131 | $141,375 | $60,514 | 42.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 339 | 542 | $81,300 | $34,239 | 42.1% |
About Dr. Jamil Ahmed, MD
Dr. Jamil Ahmed, MD is a Pulmonary Disease healthcare provider based in Fairmont, West Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1801830385.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jamil Ahmed, MD has received a total of $2,855 in payments from pharmaceutical and medical device companies, with $1,016 received in 2024. These payments were reported across 147 transactions from 13 companies. The most common payment nature is "Food and Beverage" ($2,765).
As a Medicare-enrolled provider, Ahmed has provided services to 6,959 Medicare beneficiaries, totaling 11,892 services with total Medicare billing of $714,169. Data is available for 4 years (2020–2023), covering 49 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Fairmont, WV
- Active Since 06/15/2006
- Last Updated 08/28/2025
- Taxonomy Code 207RP1001X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1801830385
Products in Payments
- FASENRA (Biological) $515.10
- SYMBICORT (Drug) $332.10
- TEZSPIRE (Biological) $243.56
- OFEV (Drug) $222.12
- BREZTRI (Drug) $214.55
- TRELEGY ELLIPTA (Drug) $171.40
- NUCALA (Biological) $145.01
- ELIQUIS (Drug) $108.98
- BREZTRI AEROSPHERE (Drug) $69.61
- AVYCAZ (Drug) $68.68
- BRILINTA (Drug) $66.01
- ANORO (Drug) $61.93
- TEFLARO (Drug) $59.48
- AirDuo Digihaler (Drug) $57.01
- STIOLTO RESPIMAT (Drug) $49.50
- ANORO ELLIPTA (Drug) $46.49
- Esbriet (Biological) $38.00
- AIRSUPRA (Drug) $30.69
- AREXVY (Drug) $28.85
- SPIRIVA RESPIMAT (Drug) $24.59
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.